Recent Finacing
Recent Raise
Tallac Therapeutics is a Burlingame-based biotech developing TRAAC antibody–TLR9 conjugates to systemically activate innate and adaptive anti-tumor immunity for solid tumors, with lead candidate TAC-001 in Phase 1/2.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Tallac Therapeutics.
